The antifungal agents available today are mostly fungistatic, requiring a prolonged course of therapy. Although models of Aspergillus and Candida have been established, there are no reliable animal models of Fusarium keratitis. Fungi considered to be ocular pathogens are rarely encountered among the systemic mycoses. Thus, the therapeutic principles valid for systemic fungal infections may not apply to the cornea. In vitro antifungal sensitivities often are performed to assess resistance patterns of the fungal isolate. However, in vitro susceptibility testing may not correspond with in vivo clinical response because of host factors, corneal penetration of the antifungal, and difficulty in standardization of antifungal sensitivities. In this chapter, treatment options and availability of antifungal agents like Polyenes (Natamycin, Amphotericin B) and azole compounds (Econazole, Clotrimazole, Imidazole, Fluconazole, voriconazole) are explained in detail in addition with diagrammatic explanation for the preparation of Amphotericin B eye drops.